Regeneron Pharmaceuticals (REGN) Non-cash Items (2009 - 2026)

Regeneron Pharmaceuticals' Non-cash Items history runs 18 years deep, the most recent figure standing at -$483.9 million for Q2 2026.

• In Q2 2026, Non-cash Items fell 95.75% year-over-year to -$483.9 million; the TTM figure through Jun 2026 stood at $352.6 million (up 23.76% YoY), while the FY2025 annual figure was $474.0 million, up 5900.0% from the prior year.
• Non-cash Items for Q2 2026 stood at -$483.9 million, down from $351.7 million in the prior quarter.
• The five-year high for Non-cash Items was $1.1 billion in Q1 2022, with the low at -$1.1 billion in Q2 2024.
• The 5-year median for Non-cash Items is $132.6 million (2023), against an average of $92.6 million.
• Peak annual rise in Non-cash Items reached 593.71% in 2024, while the deepest fall reached 2096.85% in 2024.
• Regeneron Pharmaceuticals' Non-cash Items stood at $522.8 million in 2022, then tumbled by 113.37% to -$69.9 million in 2023, then jumped by 593.71% to $345.1 million in 2024, then retreated by 5.51% to $326.1 million in 2025, then tumbled by 248.39% to -$483.9 million in 2026.
• Business Quant data shows REGN's Non-cash Items at -$483.9 million in Q2 2026, $351.7 million in Q1 2026, and $326.1 million in Q4 2025.